Carl Zeiss Meditec to Acquire Visionary Portfolio company IanTECH
Zeiss acquires Visionary portfolio company IanTECH to expand its portfolio in cataract surgery.
Zeiss acquires Visionary portfolio company IanTECH to expand its portfolio in cataract surgery.
Orasis announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directors.
Elad Kedar discusses the presbyopia market and the Orasis product.
Jeffry Weinhuff, discusses how ophthalmologists, entrepreneurs, strategic buyers, and venture capitalists partner for success.
Visionary’s portfolio company Tear Film Innovations’ iLux spotlighted in an Ophthalmology Management Article about Treatment of Meibomian gland disfunction (MGD).
Orasis Pharmaceuticals completes $13MM Series B financing led by Visionary Ventures, with participation from Sequoia Capital, SBI (Japan) Innovation Ventures, LifeSci Venture Partners, and other private investors
Tear Film Innovations completes $8.5MM Series B financing co-led by Visionary Ventures and Bluestem Capital
Tear Film Innovations completes $9MM Series A financing co-led by Visionary Ventures and Tigris Ventures
PWC Healthcare MoneyTree Report Q2 2017 Names Visionary Ventures the Number 3 Most Active Venture Fund in Healthcare.
Funding for IanTECH’s Next Generation Ophthalmic Device Supports Goal to Alleviate Cataract-induced Blindness in 25 Million.